Literature DB >> 9073059

Extremity and non-extremity high-grade osteosarcoma -- the Norwegian Radium Hospital experience during the modern chemotherapy era.

G Saeter1, O S Bruland, G Follerås, M Boysen, J Høie.   

Abstract

Of 103 patients with high-grade osteosarcoma, 27% had tumours localized outside the extremities. Non-extremity patients were significantly older at diagnosis than patients with extremity tumours (median 38 vs. 17 years). More than 90% of patients with extremity tumours received adequate treatment (aggressive chemotherapy plus at least marginal surgery), compared with only 25% of patients with non-extremity tumours. Failure of adequate treatment was due to inoperable tumour, intralesional surgery and age preventing aggressive chemotherapy. There was a highly significant difference in both local tumour control and overall survival, both favouring patients with extremity tumours. Within the extremity tumour group, patients who were treated in prospective multicentre trials had a significantly better outcome than non-trial patients. Our results show that the fraction of patients with high-grade tumours that fall outside trials designed for 'classical osteosarcoma' may be larger than is usually acknowledged, and that the results reported for the classical group are by no means representative of the whole patient population. Improved and new treatment approaches are needed for patients with non-extremity tumours, particularly in the older age groups.

Entities:  

Mesh:

Year:  1996        PMID: 9073059     DOI: 10.3109/02841869609098531

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  7 in total

1.  Prevalence of Metastasis at Diagnosis of Osteosarcoma: An International Comparison.

Authors:  Tracy A Marko; Brandon J Diessner; Logan G Spector
Journal:  Pediatr Blood Cancer       Date:  2016-02-29       Impact factor: 3.167

2.  Multimodal treatment of craniofacial osteosarcoma with high-grade histology. A single-center experience over 35 years.

Authors:  Marton König; Terje A Osnes; Ingvild Lobmaier; Bodil Bjerkehagen; Øyvind S Bruland; Kirsten Sundby Hall; Torstein R Meling
Journal:  Neurosurg Rev       Date:  2016-11-17       Impact factor: 3.042

3.  Multimodal treatment of osteogenic sarcoma of the jaw.

Authors:  Marton König; Jon Mork; Kirsten S Hall; Terje Osnes; Torstein R Meling
Journal:  Skull Base       Date:  2010-05

4.  Outcome of flat bone sarcomas (other than Ewing's) in children and adolescents: a study of 25 cases.

Authors:  V Minard-Colin; C Kalifa; J-M Guinebretiere; L Brugieres; J Dubousset; J-L Habrand; G Vassal; O Hartmann
Journal:  Br J Cancer       Date:  2004-02-09       Impact factor: 7.640

5.  Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma.

Authors:  Kjetil Berner; Tom Børge Johannesen; Aasmund Berner; Hans Kristian Haugland; Bodil Bjerkehagen; Per J Bøhler; Øyvind S Bruland
Journal:  Acta Oncol       Date:  2014-06-24       Impact factor: 4.089

6.  Prognostic factors and treatment results of high-grade osteosarcoma in norway: a scope beyond the "classical" patient.

Authors:  Kjetil Berner; Kirsten Sundby Hall; Odd R Monge; Harald Weedon-Fekjær; Olga Zaikova; Øyvind S Bruland
Journal:  Sarcoma       Date:  2015-02-17

7.  Chemotherapy in primary osteogenic sarcoma in patients over the age of forty.

Authors:  Bulent Ozkurt; Kerem Basarir; Bulent Yalcin; Abdullah Merter; Yusuf Yildiz; Yener Saglik
Journal:  Acta Orthop Traumatol Turc       Date:  2017-02-16       Impact factor: 1.511

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.